心脏代谢性休克:了解下行螺旋的最后转
Tobin Mathew1, Jin Kyung Kim1, Michael A Gibson2
1Division of Cardiology, Department of Medicine, University of California, Irvine, CA, United States.
Frontiers in cardiovascular medicine
|October 15, 2025
概括
心脏性休克 (CS) 是一种严重的疾病,死亡率高. 本综述侧重于心脏代谢性休克,这是一个复杂的CS亚型,具有代谢障碍和炎症,需要进一步研究有效的治疗方法.
科学领域:
- 心脏病学 心脏病学
- 关键护理医学 关键护理医学
- 病理生理学 病理生理学
背景情况:
- 心脏性休克 (CS) 是一种严重的疾病,其特点是心脏输出减少,导致血液动力学崩和末端器官损伤.
- CS是一种异质的状态,具有不同的原因,严重程度和血液动力学特征.
- 现有的分类,如SCAI和AHA表型,试图描述CS.
研究的目的:
- 要审查心脏代谢性休克 (CMS),一种严重的CS亚型.
- 阐明CMS复杂的病理生理学,包括代谢障碍,炎症和右心力衰竭.
- 讨论新兴的治疗策略和进一步研究的需要.
主要方法:
- 关于心脏代谢休克的文献综述.
- 对现有的CS分类和血液动力学表型的分析.
- 讨论病理生理成分和潜在的治疗点.
主要成果:
- 心脏代谢性休克是由严重的乳酸,代谢障碍,全身炎症,缺血/再输损伤,血管扩张和右心力衰竭定义的.
- 这些因素有助于逐渐的末端器官衰竭和心血管不稳定.
- 了解CMS病理生理学对于诊断和及时治疗至关重要.
结论:
- 心脏代谢性休克是一种严重的CS形式,具有代谢,炎症和血液动力学因素的复杂相互作用.
- 新兴的研究领域包括氧化合成酶抑制,抗氧化剂,抗炎剂,蛋白质组学和人工智能.
- 进一步的研究是必不可少的,以充分理解CMS和开发有针对性的,有效的治疗方法.
相关概念视频
01:24Blood Pressure Imbalances and Circulatory Shock
1.5K
Disorders affecting blood volume, vascular tone, or vascular function can disrupt vascular homeostasis, including conditions like hypertension, hemorrhage, and shock.
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
1.5K
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
655
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
655
01:30Cardiomyopathy II: Dilated Cardiomyopathy
468
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
468
01:29Heart Failure II: Pathophysiology
722
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
722
01:17Pathophysiology of Heart Failure
2.9K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.9K
01:30Heart Failure V: Medical Management
218
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
218